New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
21:05 EDTILMN, GNOMIllumina confirms failed bid for Complete Genomics
Illumina (ILMN) confirmed in a regulatory filing that it is “Party H” as named in the Schedule 14D-9 filed by Complete Genomics (GNOM) in connection with the tender offer by Beta Acquisition Corporation, a wholly owned subsidiary of BGI-Shenzhen, to purchase all of the outstanding common stock of Complete Genomics. Illumina further confirmed that it submitted proposals to acquire Complete Genomics. Illumina’s most recent proposal, submitted on November 5, included the following terms: a per share cash purchase price of $3.30, which represented approximately a 5% premium over the consideration offered by BGI; financed with cash-on-hand; and without any condition for further due diligence. Complete Genomics called Illumina's offer inadequate.
News For ILMN;GNOM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
09:44 EDTILMNIllumina participates in a conference call with JPMorgan
Subscribe for More Information
May 19, 2015
09:18 EDTILMNBofA/Merrill life sciences analysts hold an analyst/industry conference call
Analysts, along with Nancy J. Kelley, a nationally recognized executive and lawyer who has championed the field of Synthetic/Engineering Biology in the U.S., discuss what Synthetic Biology is and whether it will disrupt the Healthcare landscape and how Synthetic Biologic-based products would be regulated on an Analyst/Industry conference call to be held on May 19 at 2 pm.
May 18, 2015
16:07 EDTILMNIllumina files new patent infringement suit against Roche unit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use